RecruitingPhase 4

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

United States16 participantsStarted 2026-02-23

Plain-language summary

A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Cancer therapies, including chemotherapy, radiation, biologics or kinase inhibitors, or major surgery within 4 weeks prior to the first scheduled study treatment; for longer acting agents such as nitrosourea, mitomycin or antibody therapies, a minimum of 6 weeks.
✕. Use of investigational agents within 4 weeks prior to study enrollment (within 6 weeks if the treatment was with a long-acting agent).

What they're measuring

Area Under the Plasma Concentration-Time Curve (AUC) of Probe Drugs

Timeframe: Up to 96 hours after each probe drug administration.

Maximum Plasma Concentration (Cmax) of Probe Drugs

Timeframe: Up to 96 hours after each probe drug administration.

Trial details

NCT IDNCT07486713

SponsorRigel Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-04-30

Contact for this trial

Kay Patel

(650) 624-1100 kpatel@rigel.com

View on ClinicalTrials.gov More AML (Acute Myeloid Leukemia) trials